Pharmaceutical company Venus Remedies joins AMR Industry Alliance
Pharmaceutical company Venus Remedies said on Monday it had joined the AMR Industry Alliance – a league of more than 100 world-renowned organizations – to develop solutions to combat the serious public health threat posed by antimicrobial resistance.
Welcoming Venus Remedies as a new member, Melissa Mitchell, Head of the Antimicrobial Resistance (AMR) Industry Alliance Secretariat, said, “We are delighted to have Venus Remedies join our ranks.”
“As an organization, they are leading by example and making commendable efforts to counter the threat of AMR by improving access to AMR-relevant medications in third world countries and encouraging the appropriate use of antibiotics, as well as good management activities.
“Leading life sciences companies, like Venus Remedies, are playing a vital role in AMR mitigation and continue to strengthen multi-stakeholder collaborations,” Mitchell said in the release.
AMR Industry Alliance is the largest private sector coalition working to combat antimicrobial resistance through a coordinated, multi-pronged response.
Since its creation in 2017, it has continuously contributed to sustainable solutions to combat antimicrobial resistance by creating a broad industrial dynamic and facilitating collaboration between the public and private sectors.
Members of the alliance include R&D-based pharmaceutical, generics, diagnostics and biotechnology companies, as well as industry associations.
In addition to promoting innovation to prevent, diagnose and treat drug-resistant infections, this global coalition controls the emergence of resistance through appropriate use, addresses barriers to patient access to appropriate drugs and advances responsible manufacturing.
It is an honor to collaborate with the global life sciences industry under the umbrella of the AMR Industry Alliance and to design sustainable solutions to RAM.
“I hope this association will amplify our existing efforts against AMR globally by shaping relevant AMR policies and plugging the leaks in the current landscape of antibiotic research and manufacturing with a focus on on access and appropriate use,” said Saransh Chaudhary, CEO of Venus Medicine. Research Center (VMRC), said.
Joining Venus Remedies’ AMR Industry Alliance, which has played a commendable role in ensuring proper manufacturing and access to antibiotics, is part of the company’s ongoing efforts to partner with other organizations in a determined fight against AMR globally, the statement said. mentioned.
Present in 80 countries, Venus Remedies has enabled the sustainable supply of quality-assured antibiotics to countries that did not have ready access to them, Chaudhary said.
“Venus Remedies is one of the very few R&D-based pharmaceutical companies in the world that has focused on AMR for over a decade now. Many of its superbug solutions and last-line generic antibiotics have helped millions of patients and prevented the spread of bacterial resistance. from species to species,” the company said.
Tags attributed to this article: